HCMT
CHRS icon

Highland Capital Management (Texas)’s Coherus Oncology CHRS Stock Holding History

Highland Capital Management (Texas)’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		$2.65M Sell
119,825
-59,300
-33% -$1.03M 0.15% 116
2019
Q1 		$2.44M Sell
179,125
-51,000
-22% -$680K 0.15% 139
2018
Q4 		$2.08M Buy
230,125
+37,900
+20% +$439K 0.16% 113
2018
Q3 		$3.17M Sell
192,225
-70,555
-27% -$1.25M 0.18% 106
2018
Q2 		$3.68M Sell
262,780
-82,973
-24% -$1.19M 0.21% 97
2018
Q1 		$3.82M Sell
345,753
-146,577
-30% -$1.6M 0.2% 104
2017
Q4 		$4.33M Buy
492,330
+58,400
+13% +$625K 0.2% 106
2017
Q3 		$5.79M Buy
433,930
+55,700
+15% +$737K 0.26% 82
2017
Q2 		$5.43M Hold
378,230
– – 0.23% 91
2017
Q1 		$8M Buy
378,230
+20,975
+6% +$516K 0.41% 60
2016
Q4 		$10.1M Sell
357,255
-15,250
-4% -$427K 0.47% 59
2016
Q3 		$9.98M Buy
372,505
+45,461
+14% +$1.24M 0.3% 70
2016
Q2 		$5.52M Buy
+327,044
New +$6.14M 0.23% 109
2016
Q1 		– Sell
-223,662
Closed -$5.13M – 217
2015
Q4 		$5.13M Buy
223,662
+61,262
+38% +$1.58M 0.16% 137
2015
Q3 		$3.25M Sell
162,400
-40,400
-20% -$1.23M 0.09% 166
2015
Q2 		$5.86M Buy
202,800
+39,756
+24% +$1.01M 0.12% 151
2015
Q1 		$4.99M Buy
+163,044
New +$4.21M 0.1% 151

Other funds holding CHRS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Highland Capital Management (Texas)'s CHRS Position: Q2 2019 in Review

Highland Capital Management (Texas) reduced its Coherus Oncology (CHRS) stake by 33% in Q2 2019, selling an estimated $1.03M and leaving 119,825 shares worth $2.65M. The position accounts for 0.15% of the portfolio, ranked #116.

Highland Capital Management (Texas) first reported a position in CHRS in Q1 2015 and has held it in 17 quarters since. The position peaked at $10.1M in Q4 2016. 146 funds tracked by Wall St. Rank hold CHRS as of Q2 2019.

  • Highland Capital Management (Texas) held 119,825 shares of Coherus Oncology worth $2.65M as of Q2 2019.
  • Highland Capital Management (Texas) sold 59,300 Coherus Oncology shares in Q2 2019, an estimated $1.03M.
  • Coherus Oncology made up 0.15% of Highland Capital Management (Texas)'s portfolio in Q2 2019, its #116 holding.
  • Highland Capital Management (Texas) first reported a position in Coherus Oncology in Q1 2015 and has held it in 17 quarters since.
  • Highland Capital Management (Texas)'s Coherus Oncology position peaked at $10.1M in Q4 2016.
  • 146 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2019.

Based on Highland Capital Management (Texas)'s 13F filing for Q2 2019, filed 14 Aug 2019.